EFEITOS HEPATOPROTETORES DA CURCUMINA NA DOENÇA HEPÁTICA GORDUROSA NÃO ALCOÓLICA: MECANISMOS E EVIDÊNCIAS CLÍNICAS
DOI:
https://doi.org/10.56238/arev7n12-349Palavras-chave:
Curcumina, DHGNA, Hepatoproteção, Inflamação, Estresse OxidativoResumo
A curcumina, principal composto bioativo da Curcuma longa, apresenta propriedades anti-inflamatórias e antioxidantes com potencial terapêutico na doença hepática gordurosa não alcoólica (DHGNA). Este artigo revisa seus mecanismos de ação e evidências clínicas como agente hepatoprotetor. A curcumina modula vias inflamatórias suprimindo citocinas pró-inflamatórias (IL-1β, IL-6, TNF-α) e ativando vias como TLR4/NF-κB e AMPK, reduzindo o estresse oxidativo e a inflamação hepática. Estudos indicam que a suplementação com curcumina melhora parâmetros metabólicos, incluindo circunferência abdominal e triglicerídeos, além de reduzir a fibrose hepática. No entanto, seu efeito sobre as enzimas hepáticas é variável e sua baixa biodisponibilidade limita a eficácia clínica. A curcumina demonstra efeitos hepatoprotetores promissores na DHGNA, principalmente por meio da modulação da inflamação e do metabolismo lipídico. Contudo, mais pesquisas são necessárias para superar desafios como a biodisponibilidade e para estabelecer protocolos terapêuticos otimizados.
Downloads
Referências
Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007). Bioavailability of curcumin: Problems and promises. Molecular Pharmaceutics, 4(6), 807–818. https://doi.org/10.1021/mp700113r DOI: https://doi.org/10.1021/mp700113r
Ashraf, A., Rather, S. A., & Mehraj, M. (2025). Evaluation of Curcuma zedoaria Rosc. in the management of non-alcoholic fatty liver disease: A randomized, single blind, controlled trial. Arab Journal of Gastroenterology, 26(1), 112–119. DOI: https://doi.org/10.1016/j.ajg.2025.01.004
Cerletti, C., et al. (2020). Randomised trial of chronic supplementation with a nutraceutical mixture in subjects with non-alcoholic fatty liver disease. British Journal of Nutrition, 123(2), 190–197. https://doi.org/10.1017/S0007114519002634 DOI: https://doi.org/10.1017/S0007114519002484
Chashmniam, S., Mirhafez, S. R., Dehabeh, M., Hariri, M., Azimi Nezhad, M., & Nobakht M. Gh, B. F. (2019). A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. European Journal of Clinical Nutrition, 73(9), 1224–1235. https://doi.org/10.1038/s41430-018-0386-5 DOI: https://doi.org/10.1038/s41430-018-0386-5
Cicero, A. F. G., Sahebkar, A., Fogacci, F., Bove, M., Giovannini, M., & Borghi, C. (2020). Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: A double-blind, placebo-controlled clinical trial. European Journal of Nutrition, 59(2), 477–483. https://doi.org/10.1007/s00394-019-01916-7 DOI: https://doi.org/10.1007/s00394-019-01916-7
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018). Mechanisms of NAFLD development and therapeutic strategies. Nature Medicine, 24(7), 908–922. https://doi.org/10.1038/s41591-018-0104-9 DOI: https://doi.org/10.1038/s41591-018-0104-9
Hariri, M., Gholami, A., Mirhafez, S. R., Bidkhori, M., & Sahebkar, A. (2020). A pilot study of the effect of curcumin on epigenetic changes and DNA damage among patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, clinical trial. Complementary Therapies in Medicine, 51, 102447. https://doi.org/10.1016/j.ctim.2020.102447 DOI: https://doi.org/10.1016/j.ctim.2020.102447
He, Y., Chen, X., Li, Y., Liang, Y., Hong, T., Yang, J., Cao, Z., Mai, H., Yao, J., Zhang, T., Wu, K., Zou, J., & Feng, D. (2024). Curcumin supplementation alleviates hepatic fat content associated with modulation of gut microbiota-dependent bile acid metabolism in patients with nonalcoholic simple fatty liver disease: A randomized controlled trial. The American Journal of Clinical Nutrition, 120(1), 66–79. https://doi.org/10.1016/j.ajcnut.2024.05.017 DOI: https://doi.org/10.1016/j.ajcnut.2024.05.017
Hemati, S., Mehrabinejad, F., Elhaie, M., & Najafizade, N. (2025). Curcumin supplementation as a preventive strategy against tamoxifen-induced nonalcoholic fatty liver disease in ER+ breast cancer patients: A triple-blind randomized placebo-controlled trial. Journal of Dietary Supplements, 22(2), 274–283. https://doi.org/10.1080/19390211.2025.2465412 DOI: https://doi.org/10.1080/19390211.2025.2465412
Hewlings, S. J., & Kalman, D. S. (2017). Curcumin: A review of its effects on human health. Foods, 6(10), 92. https://doi.org/10.3390/foods6100092 DOI: https://doi.org/10.3390/foods6100092
Jazayeri-Tehrani, S. A., Rezayat, S. M., Mansouri, S., Qorbani, M., Alavian, S. M., Daneshi-Maskooni, M., & Hosseinzadeh-Attar, M. J. (2017). Efficacy of nanocurcumin supplementation on insulin resistance, lipids, inflammatory factors and nesfatin among obese patients with non-alcoholic fatty liver disease (NAFLD): A trial protocol. BMJ Open, 7(7), e016914. https://doi.org/10.1136/bmjopen-2017-016914 DOI: https://doi.org/10.1136/bmjopen-2017-016914
Kazmi, I., Al-Abbasi, F. A., Imam, S. S., Afzal, M., Nadeem, M. S., Altayb, H. N., & Alshehri, S. (2022). Formulation of piperine nanoparticles: In vitro breast cancer cell line and in vivo evaluation. Polymers, 14(7), 1349. https://doi.org/10.3390/polym14071349 DOI: https://doi.org/10.3390/polym14071349
Mirhafez, S. R., Farimani, A. R., Gholami, A., Hooshmand, E., Tavallaie, S., & Nobakht M. Gh, B. F. (2019). The effect of curcumin with piperine supplementation on pro-oxidant and antioxidant balance in patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. Drug Metabolism and Personalized Therapy, 34(2). https://doi.org/10.1515/dmpt-2018-0040 DOI: https://doi.org/10.1515/dmpt-2018-0040
Mirhafez, S. R., Dehabeh, M., Hariri, M., Farimani, A. R., Movahedi, A., Naderan, R. D., Jamialahmadi, T., Simental-Mendía, L. E., & Sahebkar, A. (2021). Curcumin and piperine combination for the treatment of patients with non-alcoholic fatty liver disease: A double-blind randomized placebo-controlled trial. Advances in Experimental Medicine and Biology, 1328, 11–19. https://doi.org/10.1007/978-3-030-73234-9_2 DOI: https://doi.org/10.1007/978-3-030-73234-9_2
Mirhafez, S. R., Azimi-Nezhad, M., Dehabeh, M., Hariri, M., Naderan, R. D., Movahedi, A., Abdalla, M., Sathyapalan, T., & Sahebkar, A. (2021). The effect of curcumin phytosome on the treatment of patients with non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled trial. Advances in Experimental Medicine and Biology, 1308, 25–35. https://doi.org/10.1007/978-3-030-64872-5_3 DOI: https://doi.org/10.1007/978-3-030-64872-5_3
Mirhafez, S. R., Rezai, A., Dehabeh, M., Nobakht M. Gh, B. F., Bidkhori, M., Sahebkar, A., & Hariri, M. (2021). Efficacy of phytosomal curcumin among patients with non-alcoholic fatty liver disease. International Journal for Vitamin and Nutrition Research, 91(3-4), 278–286. https://doi.org/10.1024/0300-9831/a000629 DOI: https://doi.org/10.1024/0300-9831/a000629
Moradi Kelardeh, B., Rahmati-Ahmadabad, S., Farzanegi, P., Helalizadeh, M., & Azarbayjani, M.-A. (2020). Effects of non-linear resistance training and curcumin supplementation on the liver biochemical markers levels and structure in older women with non-alcoholic fatty liver disease. Journal of Bodywork and Movement Therapies, 24(3), 154–160. https://doi.org/10.1016/j.jbmt.2020.02.021 DOI: https://doi.org/10.1016/j.jbmt.2020.02.021
Musso, G., Pinach, S., Mariano, F., Saba, F., De Michieli, F., Framarin, L., Berrutti, M., Paschetta, E., Parente, R., Castillo, Y. L., Leone, N., Castellino, F., Cassader, M., & Gambino, R. (2025). Effect of phospholipid curcumin Meriva on liver histology and kidney disease in nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial. Hepatology, 81(2), 560–575. https://doi.org/10.1097/HEP.0000000000000937 DOI: https://doi.org/10.1097/HEP.0000000000000937
Naseri, K., Saadati, S., Yari, Z., Askari, B., Mafi, D., Hoseinian, P., Asbaghi, O., Hekmatdoost, A., & de Courten, B. (2022). Curcumin offers no additional benefit to lifestyle intervention on cardiometabolic status in patients with non-alcoholic fatty liver disease. Nutrients, 14(15), 3224. https://doi.org/10.3390/nu14153224 DOI: https://doi.org/10.3390/nu14153224
Panahi, Y., Kianpour, P., Mohtashami, R., Jafari, R., Simental-Mendía, L. E., & Sahebkar, A. (2016). Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: A randomized controlled trial. Journal of Cardiovascular Pharmacology, 68(3), 223–229. https://doi.org/10.1097/FJC.0000000000000406 DOI: https://doi.org/10.1097/FJC.0000000000000406
Panahi, Y., Kianpour, P., Mohtashami, R., Jafari, R., Simental-Mendía, L. E., & Sahebkar, A. (2017). Efficacy and safety of phytosomal curcumin in non-alcoholic fatty liver disease: A randomized controlled trial. Drug Research, 67(4), 244–251. https://doi.org/10.1055/s-0043-100019 DOI: https://doi.org/10.1055/s-0043-100019
Panahi, Y., Valizadegan, G., Ahamdi, N., Ganjali, S., Majeed, M., & Sahebkar, A. (2019). Curcuminoids plus piperine improve nonalcoholic fatty liver disease: A clinical trial. Journal of Cellular Biochemistry, 120(9), 15989–15996. https://doi.org/10.1002/jcb.28877 DOI: https://doi.org/10.1002/jcb.28877
Qiu, L., Gao, C., Wang, H., Ren, Y., Li, J., Li, M., Du, X., Li, W., & Zhang, J. (2023). Effects of dietary polyphenol curcumin supplementation on metabolic, inflammatory, and oxidative stress indices in patients with metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Endocrinology, 14, 1216708. https://doi.org/10.3389/fendo.2023.1216708 DOI: https://doi.org/10.3389/fendo.2023.1216708
Rahmani, S., Asgary, S., Askari, G., Keshvari, M., Hatamipour, M., Feizi, A., & Sahebkar, A. (2016). Treatment of non-alcoholic fatty liver disease with curcumin: A randomized placebo-controlled trial. Phytotherapy Research, 30(9), 1540–1548. https://doi.org/10.1002/ptr.5659 DOI: https://doi.org/10.1002/ptr.5659
Ranneh, Y., Bedir, A. S., Abu-Elsaoud, A. M., & Al Raish, S. (2024). Polyphenol intervention ameliorates non-alcoholic fatty liver disease: An updated comprehensive systematic review. Nutrients, 16(23), 4150. https://doi.org/10.3390/nu16234150 DOI: https://doi.org/10.3390/nu16234150
Saadati, S., Hatami, B., Yari, Z., Shahrbaf, M. A., Eghtesad, S., Mansour, A., Poustchi, H., Hedayati, M., Aghajanpoor-Pasha, M., Sadeghi, A., & Hekmatdoost, A. (2019). The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease. European Journal of Clinical Nutrition, 73(3), 441–449. https://doi.org/10.1038/s41430-018-0382-9 DOI: https://doi.org/10.1038/s41430-018-0382-9
Saadati, S., Sadeghi, A., Mansour, A., Yari, Z., Poustchi, H., Hedayati, M., Hatami, B., & Hekmatdoost, A. (2019). Curcumin and inflammation in non-alcoholic fatty liver disease: A randomized, placebo controlled clinical trial. BMC Gastroenterology, 19(1), 133. https://doi.org/10.1186/s12876-019-1055-4 DOI: https://doi.org/10.1186/s12876-019-1055-4
Saberi-Karimian, M., Keshvari, M., Ghayour-Mobarhan, M., Salehizadeh, L., Rahmani, S., Behnam, B., Jamialahmadi, T., Asgary, S., & Sahebkar, A. (2020). Effects of curcuminoids on inflammatory status in patients with non-alcoholic fatty liver disease: A randomized controlled trial. Complementary Therapies in Medicine, 49, 102322. https://doi.org/10.1016/j.ctim.2020.102322 DOI: https://doi.org/10.1016/j.ctim.2020.102322
Sharifi, S., Bagherniya, M., Khoram, Z., Ebrahimi Varzaneh, A., Atkin, S. L., Jamialahmadi, T., Sahebkar, A., & Askari, G. (2023). Efficacy of curcumin plus piperine co-supplementation in moderate-to-high hepatic steatosis: A double-blind, randomized, placebo-controlled clinical trial. Phytotherapy Research, 37(6), 2217–2229. https://doi.org/10.1002/ptr.7764 DOI: https://doi.org/10.1002/ptr.7764
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018). Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nature Reviews Gastroenterology & Hepatology, 15(1), 11–20. https://doi.org/10.1038/nrgastro.2017.109 DOI: https://doi.org/10.1038/nrgastro.2017.109
